Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Cancer Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://ncbi.nlm.nih.gov/pubmed/24347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28669
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados